
    
      The drug being studied in this study is called alogliptin benzoate. Alogliptin benzoate is
      being researched to treat people who have T2DM. This study will look at the HbA1c level
      dynamics in participants with T2DM.

      The study enrolled 1409 patients. Alogliptin benzoate will be prescribed by their physician
      in accordance with the Russian summary of product characteristics (SmPC).

      This multi-center study will be conducted in the Russian Federation. The overall duration of
      study for observation will be approximately 6 months. Participants will make multiple visits
      to the clinic as assigned by each physician according to their routine practice, in every 3
      months.
    
  